` 091990 (Celltrion Healthcare Co Ltd) vs KOSPI 200 Comparison - Alpha Spread

091990
vs
KOSPI 200

Over the past 12 months, has underperformed KOSPI 200, delivering a return of 0% compared to the KOSPI 200's 2% drop.

Stocks Performance
091990 vs KOSPI 200

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
091990 vs KOSPI 200

Loading
091990
KOSPI 200
Difference

Performance By Year
091990 vs KOSPI 200

Loading
091990
KOSPI 200
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Celltrion Healthcare Co Ltd vs Peers

KOSPI 200
091990
MCK
COR
0HF3
CAH
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Celltrion Healthcare Co Ltd
Glance View

Market Cap
12.2T KRW
Industry
Health Care

Celltrion Healthcare Co Ltd has carved a distinctive niche in the competitive biotechnology landscape by capitalizing on its expertise in biosimilars, which are biopharmaceutical drugs almost identical to original products. The company's origins trace back to a broader vision of democratizing healthcare, striving to make biologic treatments more accessible and affordable worldwide. With its roots in South Korea, Celltrion Healthcare, a subsidiary of Celltrion Inc., has harnessed cutting-edge technology to replicate complex biological drugs. These drugs, usually utilized for chronic conditions such as autoimmune diseases and cancer, are pivotal in offering alternatives to high-cost branded biologics. By focusing on biosimilars, Celltrion addresses both a global healthcare cost crisis and a burgeoning demand for effective therapies as aging populations grow. The business model revolves around developing, manufacturing, and distributing these biosimilars. Celltrion Healthcare primarily benefits from the lower production costs compared to innovator biologics and the subsequent market penetration achieved through competitive pricing. They have established an extensive global distribution network, which enhances their reach. Collaborations with various international partners bolster their presence in strategic markets, allowing comprehensive coverage across multiple continents. Revenue is generated from licensing agreements, direct sales, and strategic partnerships, ensuring a diversified income stream. In parallel, the company's vigorous pipeline of new products promises sustained growth, aimed at expanding their therapeutic portfolio while leveraging their expertise to outpace competitors in this burgeoning field.

Intrinsic Value
64 511.48 KRW
Overvaluation 15%
Intrinsic Value
Price
Back to Top